News | May 04, 2026
Lilly posts explosive Q1 2026 results
Lifts full-year outlook as obesity drug boom accelerates
Lifts full-year outlook as obesity drug boom accelerates
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
Minimally invasive laser-based procedure restores blood flow in complex arterial blockage, enables next-day discharge and improved mobility
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
Advisory from Apollo Spectra Hospitals highlights hydration, nutrition, and screening as key preventive measures
The collaboration will embed OpenAI’s advanced AI systems across Novo Nordisk’s global operations
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
_256_384.jpg)
Effective recovery at home begins with well-defined care plans that outline treatment protocols, recovery milestones, and monitoring requirements tailored to individual patient needs
Hyderabad-based peptide specialist strengthens complex generics credentials as Apotex prepares for U.S. commercialization of semaglutide injection
Subscribe To Our Newsletter & Stay Updated
